Organization
Academic and Community Cancer Research United
32 clinical trials
Clinical trial
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2023-03-06
Clinical trial
3T: A Phase II Single Arm Open Label Study of Tucatinib Combined With Trastuzumab and TAS-102 in Molecularly Selected Patients With HER2+ Metastatic Colorectal CancerStatus: Not yet recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination With Bevacizumab and Hypofractionated Radiotherapy in Patients With Recurrent GBMStatus: Not yet recruiting, Estimated PCD: 2026-11-30
Clinical trial
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation TherapyStatus: Active (not recruiting), Estimated PCD: 2022-06-07
Clinical trial
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2019-08-13
Clinical trial
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Status: Active (not recruiting), Estimated PCD: 2021-09-24
Clinical trial
Open Label, Phase 2, Single-Arm Study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone for High-Risk, Relapsed and Relapsed/Refractory Multiple Myeloma Patients Who Have Received 1 - 3 Prior Lines of TherapyStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene MutationsStatus: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E MutationStatus: Terminated, Estimated PCD: 2023-11-01
Clinical trial
A Phase II Study of Modified VR-CAP and Acalabrutinib as First Line Therapy for Transplant-Eligible Patients With Mantle Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-08-03
Clinical trial
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2023-03-06
Clinical trial
A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel AdenocarcinomasStatus: Active (not recruiting), Estimated PCD: 2019-01-31
Clinical trial
Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 StudyStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal CancersStatus: Active (not recruiting), Estimated PCD: 2021-08-23
Clinical trial
Multicenter, Randomized Phase II Study of Epcoritamab for Patients With Aggressive B-Cell Lymphomas Achieving a Partial Response After CD19-Directed CAR-T TherapyStatus: Not yet recruiting, Estimated PCD: 2029-12-31
Clinical trial
Tafasitamab, Lenalidomide and Venetoclax Combination Therapy for Relapsed or Refractory Mantle Cell Lymphoma (V-MIND): A Phase II Study With Safety Lead-InStatus: Recruiting, Estimated PCD: 2029-12-30
Clinical trial
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2022-07-01
Clinical trial
Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot TrialStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR AlterationsStatus: Active (not recruiting), Estimated PCD: 2022-05-13
Clinical trial
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II StudyStatus: Completed, Estimated PCD: 2022-08-15
Clinical trial
Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant ChemotherapyStatus: Recruiting, Estimated PCD: 2025-01-15
Clinical trial
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast CancerStatus: , Estimated PCD: 2021-02-11
Clinical trial
A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus BevacizumabStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2027-04-04
Clinical trial
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabStatus: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)Status: Completed, Estimated PCD: 2017-09-01
Clinical trial
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)Status: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid CancersStatus: Active (not recruiting), Estimated PCD: 2020-07-17
Clinical trial
A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced CholangiocarcinomaStatus: Terminated, Estimated PCD: 2023-12-01
Clinical trial
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)Status: Active (not recruiting), Estimated PCD: 2021-03-31
Clinical trial
Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients With High-Risk Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-05